Organogenesis starts rolling submission for ReNu allograft for knee arthritis

[Mild osteoarthritis on the knee joint - 3D Rendering]
CreVis2/iStock via Getty Images

* Organogenesis (ORGO [https://seekingalpha.com/symbol/ORGO]) said it has begun a rolling BLA submission for ReNu, its cryopreserved, amniotic suspension allograft developed for the management of symptomatic knee arthritis.
* ReNu is made of amniotic fluid cells and micronized amniotic membrane, and also contains cellular, growth factor, and extracellular matrix components.
* The application is supported by results from three randomized, controlled trials.
* Organogenesis said it anticipates the rolling BLA will be completed [https://seekingalpha.com/pr/20348580-organogenesis-announces-initiation-of-biologics-license-application-for-renu] in H1 2026.

MORE ON ORGANOGENESIS HOLDINGS

* Organogenesis: High-Tech Skin Substitute Company On Sale [https://seekingalpha.com/article/4852453-organogenesis-high-tech-skin-substitute-company-on-sale]
* Organogenesis Holdings Inc. (ORGO) Q3 2025 Earnings Call Transcript [https://seekingalpha.com/article/4840611-organogenesis-holdings-inc-orgo-q3-2025-earnings-call-transcript]
* Organogenesis: Mixed ReNu Data, But Policy Tailwinds And Growth Remain Bullish [https://seekingalpha.com/article/4826566-organogenesis-mixed-renu-data-but-policy-tailwinds-and-growth-remain-bullish]
* Organogenesis outlines 2025 revenue guidance of $500M–$525M as CMS policy shift drives growth outlook [https://seekingalpha.com/news/4518984-organogenesis-outlines-2025-revenue-guidance-of-500m-525m-as-cms-policy-shift-drives-growth]
* Organogenesis Holdings GAAP EPS of $0.11 beats by $0.05, revenue of $150.5M beats by $16.4M [https://seekingalpha.com/news/4517869-organogenesis-holdings-gaap-eps-of-011-beats-by-005-revenue-of-1505m-beats-by-164m]